GSK's Nucala (Mepolizumab) Becomes First Precision Therapy Approved for COPD, Targeting IL-5 in Eosinophilic Phenotype

Chronic Obstructive Pulmonary Disease (COPD) has long lacked precise treatment options, with over 300 million patients worldwide, 40% of whom face frequent exacerbation risks due to type 2 inflammation. GSK's Nucala (mepolizumab) has received FDA approval, becoming the first biologic targeting the eosinophilic phenotype of COPD, marking the entry of COPD into the era of "precision targeting."

Note: This article is for information exchange only. The views expressed in the article do not represent the position of Pharma Intelligence, nor are they a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.

Why FIC?

Nucala is called "first-in-class" due to its outstanding performance in breakthrough targeting, precise stratification, and cross-disease validation. It is the world’s first monoclonal antibody targeting IL-5. Interleukin-5 (IL-5) plays a key role in type 2 inflammation, regulating the growth, activation, and survival of eosinophils, as well as providing crucial signals for eosinophil migration from the bone marrow to the lungs and other organs. Nucala directly inhibits the production of eosinophils that drive inflammation by selectively recognizing and binding to IL-5, blocking its interaction with receptors on the surface of eosinophils, thereby alleviating inflammation. This represents a major breakthrough in the field of COPD treatment targets.

In terms of precise stratification, patients with BEC≥150/uL at enrollment screening or recorded BEC≥300/uL within the previous 12 months account for approximately 40% of the total COPD patient population. Traditional COPD treatment models often adopt a "one-size-fits-all" approach, whereas Nucala has broken through this limitation. By accurately identifying patient groups with specific biomarker levels, treatment can be more targeted, improving therapeutic outcomes while avoiding the potential risks and waste of medical resources associated with administering drugs to unnecessary patients.

From the perspective of cross-disease validation, Nucala has expanded its application from asthma treatment to COPD treatment. It was first approved in the United States in 2015 for the treatment of severe asthma with an eosinophilic phenotype and has demonstrated remarkable efficacy in asthma treatment.

MATINEE Trial Data Shows that Nucala Significantly Reduces Annualized Moderate to Severe Exacerbation Rate in COPD Patients

From an economic perspective, COPD exacerbations account for 70% of healthcare spending. Nucala reduces the exacerbation rate, potentially decreasing medical costs associated with hospital visits due to acute exacerbations. In the U.S., hospital visits caused by acute exacerbations incur substantial annual treatment expenses. The application of Nucala is expected to lower these costs, becoming a key factor in reducing societal expenses and alleviating the burden on the healthcare system.

In terms of scientific research implications, the data confirmed the reliability of BEC as a biomarker. Previous treatment targeting the patient group with BEC≥150/μL achieved a reduction in exacerbation rates, indicating that BEC can effectively predict the risk of disease exacerbation in patients. This will drive more targeted research and provide an important basis for subsequent drug development and treatment planning for COPD and other related diseases. Screening patients for clinical trials based on biomarkers such as BEC will improve R&D efficiency and success rates.

Note: This article is for information exchange only. The views expressed in the article do not represent the position of PharmaSmart, nor are they a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.

Asthma Progressing to COPD

The expansion of Nucala's indications from asthma to COPD represents not only an extension of the treatment field but also a disruptive upgrade in the concept of chronic disease management.

Traditional COPD treatment has long relied on "firefighting-style" interventions, using bronchodilators or corticosteroids to relieve symptoms during acute exacerbations but failing to prevent the continuous decline in lung function. Nucala shifts the treatment focus to "prevention first" by targeting IL-5 to block eosinophil-mediated type 2 inflammation, inhibiting disease progression at its root and significantly reducing the annualized risk of moderate to severe exacerbations by 21%. This transformation not only decreases patient hospitalizations and irreversible lung damage but also moves COPD management from passive response to proactive prevention.

Nucala’s Cross-Condition Application Validates the Scientific Logic of "Same Treatment for Different Diseases". Although asthma and COPD have different clinical manifestations, they share the core mechanism of Type 2 inflammatory pathways—Th2 cells, ILC2, and IL-5 cytokine-driven eosinophil infiltration. Nucala’s success in asthma has laid the foundation for its COPD indication while providing a treatment paradigm for Type 2 inflammatory diseases such as nasal polyps. This "one drug, multiple conditions" strategy not only simplifies treatment regimens but also reduces the medication burden on patients.

Nucala's "prevention-first" model not only reshapes COPD management strategies but also drives the transformation of clinical practice paradigms. The TERRANOVA study shows that most COPD patients treated with Nucala did not experience moderate to severe acute exacerbations within one year, a result significantly better than traditional therapies.

Moreover, its long-term safety data provides assurance for continued medication use. This transition from "acute intervention" to "continuous prevention and control" prompts clinicians to reassess treatment goals, placing equal emphasis on reducing exacerbation events and improving functional status, thereby constructing a more comprehensive health management framework for patients. Of course, medical insurance coverage is crucial for the widespread accessibility of Nucala. If medical insurance could cover Nucala, the financial burden on patients would be significantly reduced, allowing more eligible COPD patients to access this effective treatment.

Nucala's Cross-Boundary Breakthrough Marks the Transition of Chronic Disease Management from "Symptom-Based Treatment" to "Cause-Oriented Therapy," Opening Up New Possibilities for the Integrated Diagnosis and Treatment of Type 2 Inflammatory Diseases.

Who Can Compete in the IL-5 Target Race?

Competition in the IL-5 targeted therapy field is intensifying following Nucala's breakthrough in COPD indications, but competitors like Fasenra, Cinqair, and Dupixent continue to strategize with differentiation, making the landscape of this track increasingly dynamic.

Fasenra (Benralizumab), with its unique mechanism targeting the IL-5 receptor α, achieves "rapid clearance" by inducing eosinophil apoptosis, establishing clinical advantages in severe asthma and eosinophilic granulomatosis with polyangiitis (EGPA). Its once-every-8-weeks subcutaneous injection regimen significantly improves patient compliance. However, the COPD indication is currently in Phase III clinical trials. Nevertheless, its efficacy must face the real-world data barrier accumulated by Nucala, and the lack of clear patient stratification criteria may limit its penetration speed in the COPD field.

Cinqair (Reslizumab), as an early IL-5 inhibitor, has seen a continuously shrinking market share due to the complexity of its intravenous injection process and its limitation to being approved only for severe asthma. Despite Teva Pharmaceutical's efforts to develop a subcutaneous formulation to improve convenience, slow progress in research and development, coupled with the impact of biosimilars after patent expiration, has further compressed its survival space.

Dupixent (dupilumab), on the other hand, takes a different approach by employing a dual-target (IL-4/IL-13) strategy to cover a broader range of type 2 inflammatory pathways, demonstrating "one drug, multiple diseases" potential in atopic dermatitis, asthma, and nasal polyposis. While its mechanism of action theoretically provides more comprehensive inhibition of the inflammatory network, the dual-target approach may also increase the risk of excessive immunosuppression (e.g., increased infection rates), requiring careful safety validation, especially in COPD patients.

In contrast, Nucala's core competitiveness stems from the dual moat of "precision + time": as the only IL-5 targeted drug approved for COPD, its stratification strategy based on BEC≥150/μL directly locks in 40% of the potential benefiting population, supported by long-term safety data accumulated since its launch in 2015. Although Fasenra offers better dosing convenience and Dupixent has a broader mechanism coverage, Nucala firmly secures its position as the clinical first choice through indication exclusivity and stratified precision.

Future competition in the赛道 will focus on two key dimensions: First, indication expansion, such as Fasenra accelerating its COPD submission and Dupixent exploring combination therapies (e.g., with ICS/LABA). Second, cost accessibility, as the entry of biosimilars (e.g., Mepolizumab biosimilars) is expected to reduce treatment costs, but a balance must be struck between pharmaceutical innovation incentives and patient affordability. Additionally, advancements in precision medicine may lead to the discovery of new biomarkers (e.g., sputum eosinophil counts), further refining patient stratification and driving the IL-5赛道 to evolve from "single-point breakthroughs" to "systematic solutions."

Note: This article is for information exchange only. The views expressed in the article do not represent the position of Pharma Intelligence, nor are they a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.

Conclusion

The birth of Nucala is not only a milestone in COPD treatment but also a declaration of precision medicine in the field of chronic diseases. As science shifts from "treating symptoms" to "addressing causes," patients are welcoming not just longer lifespans but also the restoration of breathing freedom. In the future, with cost reductions and medical insurance support, this "revolution at the cellular level" may benefit billions of patients worldwide.

Reference Source:

1. GSK Official Website

2、Nucala(mepolizumab)approved by US FDA for use in adults with chronic obstructive pulmonary disease(COPD).Retrieved May 22,2025 from

https://www.businesswire.com/news/home/20250522241746/en/Nucala-mepolizumab-approved-by-US-FDA-for-use-in-adults-with-chronic-obstructive-pulmonary-disease-COPD